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A 41 year old white man presented to his general practitioner
for a routine blood pressure check. He was asymptomatic and
had an initial reading of 154/115 mm Hg. Subsequent
ambulatory blood pressure monitoring (ABPM) showed that
the average daytime reading was 137/89 mm Hg.
On further assessment he had no evidence of left ventricular
hypertrophy on electrocardiography, and no silver wiring or
other abnormalities were found on funduscopy. Laboratory tests
showed total cholesterol 6.8 mmol/L (reference range <5
mmol/L), triglycerides 5.9 mmol/L (0.45-1.69), high density
lipoprotein (HDL)-cholesterol 0.76mmol/L (>1). There was no
evidence of urinary microalbuminuria.
He drank a moderate amount of alcohol at weekends only and
smoked 10 cigarettes a day. He had a medical history of
depression and dyspepsia for which he took sertraline and
omeprazole daily. He had no family history of cardiovascular
disease (CVD).
His QRISK2 score was calculated as 10.3%. He was worried
about what this meant for his health and wanted help in making
decisions about how to proceed.
Questions
1.Which guidelines and tools could help facilitate a
discussion that leads to shared decision making with the
patient?
2.What are the important principles of lifestyle advice to
deliver?
3.Is drug treatment indicated in this patient?
4.When is referral to secondary care warranted?
Answers
1.
Which guidelines and tools could help
facilitate a discussion that leads to shared
decision making with the patient?
Short answer
The National Institute for Health and Care Excellence (NICE)
has developed a clinical guideline (CG181) on lipidmodification
for primary and secondary prevention of CVD.1 Patient decision
aids present evidence based estimates of the risks and benefits
of treatment options to help facilitate shared patient focused
decision making.
Discussion
The NICE guideline offers evidence based advice and
recommendations on the treatment of people currently with, or
at risk of, CVD. International guidelines from the European
Society of Cardiology (ESC) and the American College of
Cardiology (ACC) also provide robust guidance tailored to their
respective populations.2 3
Shared decision making is an increasingly important concept
in healthcare.4 It refers to a collaborative process whereby
healthcare decisions are made jointly by patients and their
clinicians, taking into account the best scientific evidence
available as well as values and preferences. Patient decision
aids are an important means to support this process and to
provide people with clear information about the benefits and
risks of proposed interventions and treatments.5 Unlike the
generic background information provided by patient information
leaflets, they aim to supplement the interaction between
healthcare professionals and individual patients.6 A recent
Cochrane review concluded that patient decision aids increase
patients’ involvement in decisions about their care and improve
their knowledge, although the effectiveness of strategies to
improve their adoption is uncertain, given the low quality of
evidence.7
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NICE has developed a patient decision aid on taking statins
alongside its professional guidelines on lipid modification in
CVD.8 9 The ESC and ACC guidelines also place an emphasis
on shared decision making.2 3
Patient decision aids present relative and absolute risks in
context, so that patients can better understand the benefit or
harm that an intervention, or the lack of one, may bring. They
also provide illustrations that portray information in an
accessible format.
Randomised controlled trials have shown that these tools
promote dialogue and increase joint deliberation.10 They also
focus the consultation towards the patient as the data are
reviewed.11 Evidence suggests that they do not increase the
uptake of therapy overall and may do the opposite.12
Patients should be informed about the limitations of CVD risk
assessment tools, which provide only an approximate value of
risk and may misclassify high risk status at an individual level.
CVD risk tools are not appropriate for patients with pre-existing
conditions such as type 1 diabetes, chronic kidney disease,
familial hyperlipidaemia, and microalbuminia.13
Not all patients will want to be involved in making decisions
about their health or be able to understand the information that
is presented to them.14 Patients should be offered a choice on
what they feel comfortable with—many will simply want clear
advice.15
By contrast, some patients may use self assessment tools
available online. Healthcare professionals should consider
counselling patients on the use of these tools because unexpected
or contradictory results may bemisunderstood or disregarded.16
2.
What are the important principles of lifestyle
advice to deliver?
Short answer
NICE guideline CG181 recommends discussing the benefits of
lifestyle modification with the patient before offering drugs for
primary prevention of CVD. This should include diet, physical
activity, smoking, and alcohol consumption.
Discussion
When performing risk assessment, the latest NICE guideline
recommends using the QRISK2 tool to assess the risk of CVD
for primary prevention in patients ≤84 years of age.1 17QRISK2
is an algorithm that calculates the likelihood of a CVD event in
the next 10 years using validated risk factors. It is considered
better calibrated for UK CVD event rates than other tools, such
as the Framingham risk tool, which is based on data from US
prospective cohort studies and is widely used in other countries.
The NICE guidance advises that patients should not be
opportunistically assessed. However, electronic primary care
records may be used to prioritise patients for review; those over
the age of 40 should have their CVD risk assessed on an ongoing
basis; those with a QRISK2 of more than 10% should be
prioritised for a formal review. Because absolute risk may be
underestimated in younger people, clinicians should consider
the use of the JBS3 (Joint British Societies’ consensus
recommendations for the prevention of cardiovascular disease)
risk calculator, which provides estimates of lifetime risk and
allows for a discussion on the potential benefits of risk factor
modification.18
The most important principle is to encourage people to
participate in reducing their risk of CVD. This involves
ascertaining any knowledge and feelings about their health.
Confidence, readiness for change, and health beliefs must also
be explored because these will affect attitudes to lifestyle
changes.19 Decisions should be made in partnership with the
patient, and clinicians should check whether the management
plan has been fully agreed.
In general, people should be encouraged to optimise their diet
and physical activity, stop smoking, and moderate their alcohol
consumption. Dietary advice should focus on a balanced diet
and the NHS Choices website offers many suggestions on
healthy cooking methods.20 Although some reports have
advocated the “Mediterranean” diet as a preferred choice
because it is supported by trial evidence, the NICE guidelines
do not use this term because of confusion about how it might
be interpreted and potential adverse economic effects for those
with limited budgets.1-23 Nevertheless, many of the components
of this diet are incorporated into NICE’s general dietary advice:
eating at least five portions of fruit and vegetables a day;
replacing starchy foods with wholegrain options; reducing sugar
intake; and eating at least two portions of fish and four to five
portions of unsalted nuts, seeds, and legumes a week.
Patients at high risk and those with pre-existing CVD should
avoid saturated fats where possible and 30% or less of their
energy intake should come from fat.
Salt intake should also be monitored and kept at 5-6 g per day,
because reducing salt can help to reduce high blood pressure.24 25
Individual circumstances should be taken into consideration,
and patients should be encouraged to have a healthy approach
to changing their behaviour in relation to food. In line with
NICE’s recommendations on obesity, weight management is
also vital, and patients who are overweight should have
discussions about achieving and maintaining a healthy weight
and be supported and guided to appropriate services to facilitate
this.26
Any advice on physical activity should also take into account
the patient’s circumstances and preferences, particularly with
respect to comorbidities and mobility. NICE recommends that
patients should follow the national guidance for physical activity
in the general population.1 People at high risk of CVD who are
capable should aim for at least 150minutes of moderate exercise
a week, or 75 minutes of vigorous exercise; or a combination
of both.27 Exercises that strengthen major muscles groups are
also recommended.
Alcohol should be moderated to 3 units a day for men and 2
units a day for women, with avoidance of heavy “binge”
drinking where possible.28 It is particularly important to deal
with the problem of smoking because in many cases smoking
cessation is one of the most effective interventions to improve
the overall CVD risk profile.29 The NHS Stop Smoking Services
offer an intensive support service for people who are trying to
quit, and depending on the assessment of nicotine dependence,
pharmacotherapy and behavioural interventions (or a
combination of both) may be considered.30
3.
Is drug treatment indicated in this patient?
Short answer
His ABPM reading represents uncomplicated stage 1
hypertension and drug treatment is not indicated according to
current NICE guidance. His CVD risk is >10% and NICE
guidance suggests considering statin treatment in this range,
but an initial period of supported lifestyle modification should
be offered first.
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Discussion
ABPM provides a more accurate diagnosis because of the
physiological variability of blood pressure and because it negates
the “white coat” effect. If ABPM is not tolerated, home blood
pressure monitoring is a suitable alternative to confirm
hypertension, with blood pressure recorded twice a day for seven
days.24 International guidelines vary in their recommendations
for starting drugs in stage 1 hypertension, owing to differences
in interpretation of the limited evidence base in this population
and differences in emphasis on cost effectiveness.31
Lifestyle interventions are the over-riding priority for patients
with a QRISK2 score just over 10% and are the mainstay of
management. If, after a period of lifestyle modification, the 10
year risk of CVD continues to be above 10% using the QRISK2
assessment tool, a statin may be offered. Any such decision to
start treatment in the future should be taken in collaboration
with the patient, and the doctor’s job is to help share knowledge
about the best available evidence of risks and benefits.
The NICE lipid guideline (CG181) suggests that when a joint
decision has been made to start statins as primary prevention
of CVD, atorvastatin 20 mg once daily should be the routine
choice. However, for patients with pre-existing cardiovascular
disease, a higher dose of 80 mg is indicated.
Statins are one of the most common types of drug prescribed
in the NHS.32Despite their widespread use and tolerability, they
have been associated with a variety of adverse effects. Myalgia
is commonly reported so it is important to ask about generalised,
unexplained muscle pains before the patient starts treatment.1
If such pains are present, creatine kinase levels should be
checked; this is also the test of choice in people who develop
symptoms while taking statins.1 There is also an increased risk
of developing type 2 diabetes while taking statins, although a
meta-analysis of statin trials found just one extra case of diabetes
in 255 patients treated with statins for four years.33 Counselling
about the possibility of developing these unintended effects is
an important part of discussions about treatment.
Advise patients who choose not to start statins, even though
their CVD risk is at a level where intervention is warranted, that
their CVD risk should be reassessed in the future.1
ESC guidelines recommend the use of the SCORE system and
low density lipoprotein levels to measure the risk of CVD.34
Both the NICE and ESC guidelines advise using a threshold of
10% with their respective scoring systems to consider starting
drug treatment and concur with the recommendations suggesting
an initial period of lifestyle intervention.2 ACC guidelines,
meanwhile, suggest the use of race and sex specific pooled
cohort equations.35 They suggest starting statins for primary
prevention in patients with a predicted 10 year risk of ≥7.5%
and consideration of statins in those with a 10 year risk of
5-7.5%.36
4.
When is referral to secondary carewarranted?
Short answer
When total cholesterol is >9.0 mmol/L or non-HDL-cholesterol
is >7.5 mmol/L. Urgent specialist review is warranted if
triglycerides are >20 mmol/L (not as a result of poor glycaemic
control or excess alcohol).1 Specialist evaluation for secondary
causes of hypertension and potential target organ damage can
be considered.
Discussion
CVD risk can mostly be managed in primary care, but specialist
lipid services should be used to optimise treatment and CVD
reduce risk further if appropriate.37 Common secondary causes
of dyslipidaemia should be excluded before a referral is made.
These include uncontrolled diabetes, hypothyroidism, liver
disease, excess alcohol intake, and nephrotic syndrome.1
A full lipid profile—total cholesterol, HDL-cholesterol,
non-HDL-cholesterol, and triglyceride concentrations—should
be measured before statins are started; a fasting sample is not
needed. Familial hypercholesterolaemia should be suspected if
total cholesterol is >7.5 mmol/L and there is a family history
of premature coronary heart disease.1
A fasting triglyceride concentration is recommended only if the
initial triglyceride concentration is 10-20 mmol/L. It should be
measured within two weeks but after five days. Seek specialist
advice if the patient’s fasting triglyceride concentration remains
above10 mmol/L.
The NICE guidelines encourage consideration of secondary
causes of hypertension in people under 40 with stage 1
hypertension and no evidence of CVD, target organ damage,
renal disease, or diabetes. A more detailed assessment of target
organ damage should be undertaken because 10 year risk
assessments can underestimate the lifetime risk of cardiovascular
events in this cohort.23
Patient outcome
The GP and patient discussed what the QRISK2 score means
and the implications for the patient’s future health. The options
for reducing his risk—lifestyle modifications and treatment with
statins—were explored.
After consideration and an initial attempt at lifestyle measures,
the patient opted for drug treatment to reduce his risk of CVD.
This decision was influenced by the use of a patient decision
aid and his personal research, and he was started on atorvastatin
20 mg once daily.
He has had no adverse effects and remains compliant with his
treatment. He is aware of the importance of continuing to make
lifestyle changes to improve his hypertension and overall
cardiovascular risk.
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